국가: 캐나다
언어: 영어
출처: Health Canada
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE)
PHARMASCIENCE INC
N06AX16
VENLAFAXINE
37.5MG
CAPSULE (EXTENDED RELEASE)
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5MG
ORAL
100/500
Prescription
SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0131294002; AHFS:
APPROVED
2007-08-17
_pms-VENLAFAXINE XR (venlafaxine hydrochloride) _ _Page 1 of 84 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PMS-VENLAFAXINE XR Venlafaxine Hydrochloride Extended Release Capsules Extended Release Capsules, 37.5 mg, 75 mg and 150 mg venlafaxine (as venlafaxine hydrochloride), Oral Antidepressant / Anxiolytic PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Québec H4P 2T4 www.pharmascience.com Submission Control Number: 270919 Date of Initial Authorization: AUG 17, 2007 Date of Revision: JAN 25, 2023 _pms-VENLAFAXINE XR (venlafaxine hydrochloride) _ _Page 2 of 84 _ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions 01/2023 7 Warnings and Precautions, 7.1 Special Populations, 7.1.1 Pregnant Women 06/2020 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS ................................................................................................................... 4 1.1 Pediatrics ....................................................................................................................... 4 1.2 Geriatrics ....................................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ...................................................................................... 5 4.1 Dosing Considerations .................................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment Adults . 전체 문서 읽기